0000049071--12-312022Q2false0.16670.1667http://fasb.org/us-gaap/2022#HealthCareMemberhttp://fasb.org/us-gaap/2022#HealthCareMemberhttp://fasb.org/us-gaap/2022#HealthCareMemberhttp://fasb.org/us-gaap/2022#HealthCareMember00000490712022-01-012022-06-3000000490712022-06-30xbrli:sharesiso4217:USD00000490712021-12-31iso4217:USDxbrli:shares00000490712022-04-012022-06-3000000490712021-04-012021-06-3000000490712021-01-012021-06-300000049071us-gaap:CommonStockMember2022-03-310000049071us-gaap:AdditionalPaidInCapitalMember2022-03-310000049071us-gaap:RetainedEarningsMember2022-03-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000049071us-gaap:TreasuryStockCommonMember2022-03-310000049071us-gaap:NoncontrollingInterestMember2022-03-3100000490712022-03-310000049071us-gaap:RetainedEarningsMember2022-04-012022-06-300000049071us-gaap:NoncontrollingInterestMember2022-04-012022-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300000049071us-gaap:TreasuryStockCommonMember2022-04-012022-06-300000049071us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300000049071us-gaap:CommonStockMember2022-04-012022-06-300000049071us-gaap:CommonStockMember2022-06-300000049071us-gaap:AdditionalPaidInCapitalMember2022-06-300000049071us-gaap:RetainedEarningsMember2022-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000049071us-gaap:TreasuryStockCommonMember2022-06-300000049071us-gaap:NoncontrollingInterestMember2022-06-300000049071us-gaap:CommonStockMember2021-03-310000049071us-gaap:AdditionalPaidInCapitalMember2021-03-310000049071us-gaap:RetainedEarningsMember2021-03-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310000049071us-gaap:TreasuryStockCommonMember2021-03-310000049071us-gaap:NoncontrollingInterestMember2021-03-3100000490712021-03-310000049071us-gaap:RetainedEarningsMember2021-04-012021-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300000049071us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300000049071us-gaap:TreasuryStockCommonMember2021-04-012021-06-300000049071us-gaap:CommonStockMember2021-06-300000049071us-gaap:AdditionalPaidInCapitalMember2021-06-300000049071us-gaap:RetainedEarningsMember2021-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000049071us-gaap:TreasuryStockCommonMember2021-06-300000049071us-gaap:NoncontrollingInterestMember2021-06-3000000490712021-06-300000049071us-gaap:CommonStockMember2021-12-310000049071us-gaap:AdditionalPaidInCapitalMember2021-12-310000049071us-gaap:RetainedEarningsMember2021-12-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000049071us-gaap:TreasuryStockCommonMember2021-12-310000049071us-gaap:NoncontrollingInterestMember2021-12-310000049071us-gaap:RetainedEarningsMember2022-01-012022-06-300000049071us-gaap:NoncontrollingInterestMember2022-01-012022-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300000049071us-gaap:TreasuryStockCommonMember2022-01-012022-06-300000049071us-gaap:AdditionalPaidInCapitalMember2022-01-012022-06-300000049071us-gaap:CommonStockMember2022-01-012022-06-300000049071us-gaap:CommonStockMember2020-12-310000049071us-gaap:AdditionalPaidInCapitalMember2020-12-310000049071us-gaap:RetainedEarningsMember2020-12-310000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000049071us-gaap:TreasuryStockCommonMember2020-12-310000049071us-gaap:NoncontrollingInterestMember2020-12-3100000490712020-12-310000049071us-gaap:RetainedEarningsMember2021-01-012021-06-300000049071us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-06-300000049071us-gaap:AdditionalPaidInCapitalMember2021-01-012021-06-300000049071us-gaap:TreasuryStockCommonMember2021-01-012021-06-300000049071hum:ValueCreationInitiativesMember2022-04-012022-06-300000049071us-gaap:ServiceMember2022-06-300000049071us-gaap:ServiceMemberus-gaap:ProductConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-06-30xbrli:pure0000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhum:KindredAtHomeHospiceAndPersonalCareDivisionsMember2022-04-210000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhum:KindredAtHomeHospiceAndPersonalCareDivisionsMember2022-06-300000049071hum:KindredAtHomeMember2022-04-012022-06-300000049071hum:KindredAtHomeMember2022-01-012022-06-300000049071hum:KindredAtHomeMember2021-08-170000049071hum:KindredAtHomeMember2021-08-172021-08-170000049071us-gaap:USTreasuryAndGovernmentMember2022-06-300000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2022-06-300000049071us-gaap:NontaxableMunicipalNotesMember2022-06-300000049071us-gaap:ResidentialMortgageBackedSecuritiesMember2022-06-300000049071us-gaap:CommercialMortgageBackedSecuritiesMember2022-06-300000049071us-gaap:AssetBackedSecuritiesMember2022-06-300000049071us-gaap:CorporateDebtSecuritiesMember2022-06-300000049071us-gaap:USTreasuryAndGovernmentMember2021-12-310000049071us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2021-12-310000049071us-gaap:NontaxableMunicipalNotesMember2021-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMember2021-12-310000049071us-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000049071us-gaap:AssetBackedSecuritiesMember2021-12-310000049071us-gaap:CorporateDebtSecuritiesMember2021-12-310000049071srt:StandardPoorsAAMinusRatingMember2022-06-30hum:position0000049071us-gaap:FairValueMeasurementsRecurringMember2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2022-06-300000049071us-gaap:FairValueMeasurementsRecurringMember2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:NontaxableMunicipalNotesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:ResidentialMortgageBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMember2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialMortgageBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2021-12-310000049071us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Member2021-12-310000049071us-gaap:FairValueInputsLevel3Memberus-gaap:InvestmentsMemberhum:FairValueRiskMember2022-01-012022-06-300000049071us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-06-300000049071us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-310000049071us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-06-300000049071us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-310000049071hum:NotesPayableToBanksAndCommercialPaperMember2022-06-300000049071hum:NotesPayableToBanksAndCommercialPaperMember2021-12-310000049071hum:KindredAtHomeMember2021-04-270000049071us-gaap:PutOptionMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-03-310000049071us-gaap:OtherNoncurrentAssetsMemberus-gaap:CallOptionMember2021-03-310000049071us-gaap:OtherNoncurrentAssetsMemberus-gaap:CallOptionMember2021-04-270000049071us-gaap:PutOptionMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-04-2700000490712021-01-012021-12-310000049071us-gaap:PutOptionMemberus-gaap:OtherNoncurrentLiabilitiesMember2022-06-300000049071us-gaap:OtherNoncurrentAssetsMemberus-gaap:CallOptionMember2022-06-300000049071us-gaap:PutOptionMemberus-gaap:OtherNoncurrentLiabilitiesMember2021-12-310000049071us-gaap:OtherNoncurrentAssetsMemberus-gaap:CallOptionMember2021-12-310000049071us-gaap:MeasurementInputOptionVolatilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMembersrt:MinimumMember2022-06-300000049071srt:MaximumMemberus-gaap:MeasurementInputOptionVolatilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2022-06-300000049071us-gaap:MeasurementInputOptionVolatilityMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2021-12-310000049071us-gaap:CreditSpreadOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMembersrt:MinimumMember2022-06-300000049071srt:MaximumMemberus-gaap:CreditSpreadOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2022-06-300000049071us-gaap:CreditSpreadOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2021-12-310000049071hum:RevenueExitMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMembersrt:MinimumMember2022-06-300000049071srt:MaximumMemberhum:RevenueExitMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2022-06-300000049071hum:RevenueExitMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMembersrt:MinimumMember2021-12-310000049071srt:MaximumMemberhum:RevenueExitMultipleMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2021-12-310000049071us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2022-06-300000049071us-gaap:MeasurementInputDiscountRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2021-12-310000049071us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2022-06-300000049071us-gaap:MeasurementInputLongTermRevenueGrowthRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OptionOnSecuritiesMember2021-12-310000049071hum:RiskCorridorSettlementsMedicarePartDMember2022-06-300000049071hum:CmsSubsidiesOrDiscountsMember2022-06-300000049071hum:RiskCorridorSettlementsMedicarePartDMember2021-12-310000049071hum:CmsSubsidiesOrDiscountsMember2021-12-310000049071hum:RetailSegmentMember2021-12-310000049071hum:GroupAndSpecialtySegmentMember2021-12-310000049071hum:HealthcareServicesSegmentMember2021-12-310000049071hum:RetailSegmentMember2022-01-012022-06-300000049071hum:GroupAndSpecialtySegmentMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMember2022-01-012022-06-300000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhum:RetailSegmentMember2022-06-300000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhum:GroupAndSpecialtySegmentMember2022-06-300000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMemberhum:HealthcareServicesSegmentMember2022-06-300000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2022-06-300000049071hum:RetailSegmentMember2022-06-300000049071hum:GroupAndSpecialtySegmentMember2022-06-300000049071hum:HealthcareServicesSegmentMember2022-06-300000049071hum:CertificateOfNeedMember2022-06-300000049071hum:CertificateOfNeedMember2021-12-310000049071us-gaap:LicensingAgreementsMember2022-06-300000049071us-gaap:LicensingAgreementsMember2021-12-310000049071us-gaap:CustomerContractsMember2022-01-012022-06-300000049071us-gaap:CustomerContractsMember2022-06-300000049071us-gaap:CustomerContractsMember2021-12-310000049071us-gaap:TradeNamesMember2022-01-012022-06-300000049071us-gaap:TradeNamesMember2022-06-300000049071us-gaap:TradeNamesMember2021-12-310000049071us-gaap:ContractualRightsMember2022-01-012022-06-300000049071us-gaap:ContractualRightsMember2022-06-300000049071us-gaap:ContractualRightsMember2021-12-310000049071hum:NoncompetesAndOtherMember2022-01-012022-06-300000049071hum:NoncompetesAndOtherMember2022-06-300000049071hum:NoncompetesAndOtherMember2021-12-310000049071us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2021-12-310000049071hum:RetailSegmentMember2020-12-310000049071hum:RetailSegmentMember2021-01-012021-06-300000049071hum:RetailSegmentMember2021-06-300000049071hum:GroupAndSpecialtySegmentMember2020-12-310000049071hum:GroupAndSpecialtySegmentMember2021-01-012021-06-300000049071hum:GroupAndSpecialtySegmentMember2021-06-300000049071us-gaap:EmployeeStockOptionMember2022-04-012022-06-300000049071us-gaap:EmployeeStockOptionMember2021-04-012021-06-300000049071us-gaap:EmployeeStockOptionMember2022-01-012022-06-300000049071us-gaap:EmployeeStockOptionMember2021-01-012021-06-300000049071us-gaap:RestrictedStockMember2022-04-012022-06-300000049071us-gaap:RestrictedStockMember2021-04-012021-06-300000049071us-gaap:RestrictedStockMember2022-01-012022-06-300000049071us-gaap:RestrictedStockMember2021-01-012021-06-3000000490712021-01-292021-01-2900000490712021-04-302021-04-3000000490712021-07-302021-07-3000000490712021-10-292021-10-2900000490712022-01-282022-01-2800000490712022-04-292022-04-2900000490712022-04-012022-04-3000000490712019-07-3000000490712021-02-180000049071hum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-110000049071hum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-120000049071hum:MizuhoMarketsAmericasLLCMemberhum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-120000049071hum:January2022AcceleratedShareRepurchaseAgreementMemberhum:WellsFargoBankMember2022-01-120000049071hum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-122022-01-120000049071hum:MizuhoMarketsAmericasLLCMemberhum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-122022-01-120000049071hum:January2022AcceleratedShareRepurchaseAgreementMemberhum:WellsFargoBankMember2022-01-122022-01-120000049071hum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-012022-01-310000049071hum:MizuhoMarketsAmericasLLCMemberhum:January2022AcceleratedShareRepurchaseAgreementMember2022-03-292022-03-290000049071hum:January2022AcceleratedShareRepurchaseAgreementMemberhum:WellsFargoBankMember2022-03-302022-03-300000049071hum:January2022AcceleratedShareRepurchaseAgreementMember2022-01-012022-06-300000049071hum:January2022AcceleratedShareRepurchaseAgreementMember2022-03-292022-03-300000049071us-gaap:SubsequentEventMember2022-07-260000049071us-gaap:CommercialPaperMember2022-06-300000049071us-gaap:CommercialPaperMember2021-12-310000049071us-gaap:SeniorNotesMemberhum:A3.15PercentSeniorNotesDueDecember2022Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A3.15PercentSeniorNotesDueDecember2022Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A2.90PercentSeniorNotesDueDecember2022Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A2.90PercentSeniorNotesDueDecember2022Member2021-12-310000049071us-gaap:SeniorNotesMember2022-06-300000049071us-gaap:SeniorNotesMember2021-12-310000049071us-gaap:SeniorNotesMemberhum:A065PercentSeniorNotesDueAugust2023Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A065PercentSeniorNotesDueAugust2023Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A3.85PercentSeniorNotesDueOctober2024Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A3.85PercentSeniorNotesDueOctober2024Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A450PercentSeniorNotesDueApril2025Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A450PercentSeniorNotesDueApril2025Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A135PercentSeniorNotesDueFebruary2027Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A135PercentSeniorNotesDueFebruary2027Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A3.95PercentSeniorNotesDueMarch2027Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A3.95PercentSeniorNotesDueMarch2027Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A3700PercentSeniorNotesDueMarch2029Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A3700PercentSeniorNotesDueMarch2029Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A3125PercentSeniorNotesDueAugust2029Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A3125PercentSeniorNotesDueAugust2029Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A4875PercentSeniorNotesDueApril2030Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A4875PercentSeniorNotesDueApril2030Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A215PercentSeniorNotesDueFebruary2032Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A215PercentSeniorNotesDueFebruary2032Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A8.15PercentSeniorNotesDueJune2038Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A8.15PercentSeniorNotesDueJune2038Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A4.625PercentSeniorNotesDueDecember2042Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A4.625PercentSeniorNotesDueDecember2042Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A4.95PercentSeniorNotesDueOctober2044Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A4.95PercentSeniorNotesDueOctober2044Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A4.80PercentSeniorNotesDueMarch2047Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A4.80PercentSeniorNotesDueMarch2047Member2021-12-310000049071us-gaap:SeniorNotesMemberhum:A395PercentSeniorNotesDueAugust2049Member2022-06-300000049071us-gaap:SeniorNotesMemberhum:A395PercentSeniorNotesDueAugust2049Member2021-12-310000049071us-gaap:LoansPayableMemberhum:TermLoanDueOctober2023Member2022-06-300000049071us-gaap:LoansPayableMemberhum:TermLoanDueOctober2023Member2021-12-310000049071hum:DelayedDrawTermLoanMay2024Memberus-gaap:LoansPayableMember2022-06-300000049071hum:DelayedDrawTermLoanMay2024Memberus-gaap:LoansPayableMember2021-12-310000049071us-gaap:LoansPayableMember2022-06-300000049071us-gaap:LoansPayableMember2021-12-310000049071us-gaap:SeniorNotesMember2022-01-012022-06-300000049071us-gaap:SeniorNotesMemberhum:A3700PercentSeniorNotesDueMarch2029Member2022-03-310000049071us-gaap:SeniorNotesMemberhum:A3700PercentSeniorNotesDueMarch2029Member2022-03-012022-03-310000049071us-gaap:LoansPayableMemberhum:DelayedDrawTermLoanMay2021Member2021-05-310000049071us-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:DelayedDrawTermLoanMay2021Member2021-05-012021-05-310000049071us-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:DelayedDrawTermLoanMay2021Membersrt:MinimumMember2021-05-012021-05-310000049071srt:MaximumMemberus-gaap:LoansPayableMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:DelayedDrawTermLoanMay2021Member2021-05-012021-05-310000049071us-gaap:LoansPayableMemberhum:DelayedDrawTermLoanMay2021Member2021-08-012021-08-310000049071hum:KindredAtHomeMember2021-08-310000049071us-gaap:LoansPayableMemberhum:DelayedDrawTermLoanMay2021Member2022-06-300000049071hum:October2021TermLoanAgreementMemberus-gaap:LoansPayableMember2021-10-290000049071hum:October2021TermLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-01-012022-06-300000049071hum:October2021TermLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMembersrt:MinimumMember2022-01-012022-06-300000049071srt:MaximumMemberhum:October2021TermLoanAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMember2022-01-012022-06-300000049071us-gaap:LoansPayableMemberhum:GentivaTermLoanDue2025Member2021-10-292021-10-290000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2021-06-012021-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2021-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021OneYearMember2022-06-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021OneYearMember2022-06-300000049071us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:RevolvingCreditAgreementJune2021OneYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021OneYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:RevolvingCreditAgreementJune2021FiveYearMembersrt:MinimumMember2022-01-012022-06-300000049071srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:RevolvingCreditAgreementJune2021OneYearMembersrt:MinimumMember2022-01-012022-06-300000049071srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LondonInterbankOfferedRateLIBORMemberhum:RevolvingCreditAgreementJune2021OneYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021FiveYearMembersrt:MinimumMember2022-01-012022-06-300000049071srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021OneYearMembersrt:MinimumMember2022-01-012022-06-300000049071srt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021OneYearMember2022-01-012022-06-300000049071us-gaap:RevolvingCreditFacilityMember2022-06-300000049071us-gaap:LetterOfCreditMember2022-06-300000049071us-gaap:RevolvingCreditFacilityMemberhum:RevolvingCreditAgreementJune2021FiveYearMember2022-06-300000049071us-gaap:CommercialPaperMember2022-02-100000049071us-gaap:CommercialPaperMember2022-01-012022-06-300000049071us-gaap:FederalHomeLoanBankAdvancesMember2022-06-300000049071hum:MedicareMember2022-01-012022-06-300000049071hum:MedicaidMember2022-01-012022-06-300000049071hum:MilitaryServiceMember2022-01-012022-06-30hum:statehum:beneficiary0000049071hum:TricareEastRegionContractMember2022-01-012022-06-30hum:segment0000049071hum:RetailSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareAdvantageMember2022-04-012022-06-300000049071hum:MedicareAdvantageMember2022-04-012022-06-300000049071hum:GroupMedicareAdvantageMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:GroupMedicareAdvantageMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:GroupMedicareAdvantageMember2022-04-012022-06-300000049071hum:GroupMedicareAdvantageMember2022-04-012022-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2022-04-012022-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMember2022-04-012022-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2022-04-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareMember2022-04-012022-06-300000049071hum:MedicareMember2022-04-012022-06-300000049071hum:RetailSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:FullyInsuredMember2022-04-012022-06-300000049071hum:FullyInsuredMember2022-04-012022-06-300000049071hum:RetailSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:SpecialtyMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:SpecialtyMember2022-04-012022-06-300000049071hum:SpecialtyMember2022-04-012022-06-300000049071hum:MedicaidAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:MedicaidAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicaidAndOtherMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicaidAndOtherMember2022-04-012022-06-300000049071hum:MedicaidAndOtherMember2022-04-012022-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMember2022-04-012022-06-300000049071hum:HomeSolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HomeSolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HomeSolutionsMemberhum:CorporateAndEliminationsMember2022-04-012022-06-300000049071hum:HomeSolutionsMember2022-04-012022-06-300000049071hum:ProviderServicesMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:ProviderServicesMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:ProviderServicesMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:ProviderServicesMember2022-04-012022-06-300000049071hum:ProviderServicesMember2022-04-012022-06-300000049071hum:ASOAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:ASOAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:ASOAndOtherMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:ASOAndOtherMember2022-04-012022-06-300000049071hum:ASOAndOtherMember2022-04-012022-06-300000049071hum:PharmacySolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:PharmacySolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:PharmacySolutionsMember2022-04-012022-06-300000049071hum:PharmacySolutionsMember2022-04-012022-06-300000049071us-gaap:ServiceMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071us-gaap:ServiceMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMember2022-04-012022-06-300000049071us-gaap:ServiceMember2022-04-012022-06-300000049071hum:RetailSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071us-gaap:ProductMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2022-04-012022-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMember2022-04-012022-06-300000049071us-gaap:ProductMember2022-04-012022-06-300000049071hum:RetailSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareAdvantageMember2021-04-012021-06-300000049071hum:MedicareAdvantageMember2021-04-012021-06-300000049071hum:GroupMedicareAdvantageMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:GroupMedicareAdvantageMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:GroupMedicareAdvantageMember2021-04-012021-06-300000049071hum:GroupMedicareAdvantageMember2021-04-012021-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2021-04-012021-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMember2021-04-012021-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2021-04-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareMember2021-04-012021-06-300000049071hum:MedicareMember2021-04-012021-06-300000049071hum:RetailSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:FullyInsuredMember2021-04-012021-06-300000049071hum:FullyInsuredMember2021-04-012021-06-300000049071hum:RetailSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:SpecialtyMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:SpecialtyMember2021-04-012021-06-300000049071hum:SpecialtyMember2021-04-012021-06-300000049071hum:MedicaidAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:MedicaidAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicaidAndOtherMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicaidAndOtherMember2021-04-012021-06-300000049071hum:MedicaidAndOtherMember2021-04-012021-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMember2021-04-012021-06-300000049071hum:HomeSolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HomeSolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HomeSolutionsMemberhum:CorporateAndEliminationsMember2021-04-012021-06-300000049071hum:HomeSolutionsMember2021-04-012021-06-300000049071hum:ProviderServicesMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:ProviderServicesMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:ProviderServicesMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:ProviderServicesMember2021-04-012021-06-300000049071hum:ProviderServicesMember2021-04-012021-06-300000049071hum:ASOAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:ASOAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:ASOAndOtherMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:ASOAndOtherMember2021-04-012021-06-300000049071hum:ASOAndOtherMember2021-04-012021-06-300000049071hum:PharmacySolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:PharmacySolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:PharmacySolutionsMember2021-04-012021-06-300000049071hum:PharmacySolutionsMember2021-04-012021-06-300000049071us-gaap:ServiceMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071us-gaap:ServiceMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMember2021-04-012021-06-300000049071us-gaap:ServiceMember2021-04-012021-06-300000049071hum:RetailSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071us-gaap:ProductMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2021-04-012021-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMember2021-04-012021-06-300000049071us-gaap:ProductMember2021-04-012021-06-300000049071hum:RetailSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareAdvantageMember2022-01-012022-06-300000049071hum:MedicareAdvantageMember2022-01-012022-06-300000049071hum:GroupMedicareAdvantageMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:GroupMedicareAdvantageMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:GroupMedicareAdvantageMember2022-01-012022-06-300000049071hum:GroupMedicareAdvantageMember2022-01-012022-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2022-01-012022-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMember2022-01-012022-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2022-01-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareMember2022-01-012022-06-300000049071hum:RetailSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:FullyInsuredMember2022-01-012022-06-300000049071hum:FullyInsuredMember2022-01-012022-06-300000049071hum:RetailSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:SpecialtyMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:SpecialtyMember2022-01-012022-06-300000049071hum:SpecialtyMember2022-01-012022-06-300000049071hum:MedicaidAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:MedicaidAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicaidAndOtherMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicaidAndOtherMember2022-01-012022-06-300000049071hum:MedicaidAndOtherMember2022-01-012022-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMember2022-01-012022-06-300000049071hum:HomeSolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HomeSolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HomeSolutionsMemberhum:CorporateAndEliminationsMember2022-01-012022-06-300000049071hum:HomeSolutionsMember2022-01-012022-06-300000049071hum:ProviderServicesMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:ProviderServicesMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:ProviderServicesMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:ProviderServicesMember2022-01-012022-06-300000049071hum:ProviderServicesMember2022-01-012022-06-300000049071hum:ASOAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:ASOAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:ASOAndOtherMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:ASOAndOtherMember2022-01-012022-06-300000049071hum:ASOAndOtherMember2022-01-012022-06-300000049071hum:PharmacySolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:PharmacySolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberhum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberhum:PharmacySolutionsMember2022-01-012022-06-300000049071hum:PharmacySolutionsMember2022-01-012022-06-300000049071us-gaap:ServiceMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071us-gaap:ServiceMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMember2022-01-012022-06-300000049071us-gaap:ServiceMember2022-01-012022-06-300000049071hum:RetailSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071us-gaap:ProductMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2022-01-012022-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMember2022-01-012022-06-300000049071us-gaap:ProductMember2022-01-012022-06-300000049071hum:RetailSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareAdvantageMember2021-01-012021-06-300000049071hum:MedicareAdvantageMember2021-01-012021-06-300000049071hum:GroupMedicareAdvantageMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:GroupMedicareAdvantageMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:GroupMedicareAdvantageMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:GroupMedicareAdvantageMember2021-01-012021-06-300000049071hum:GroupMedicareAdvantageMember2021-01-012021-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicareStandAlonePrescriptionDrugPlanMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareStandAlonePrescriptionDrugPlanMember2021-01-012021-06-300000049071hum:MedicareStandAlonePrescriptionDrugPlanMember2021-01-012021-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2021-01-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMemberhum:MedicareMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicareMember2021-01-012021-06-300000049071hum:MedicareMember2021-01-012021-06-300000049071hum:RetailSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:FullyInsuredMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:FullyInsuredMember2021-01-012021-06-300000049071hum:FullyInsuredMember2021-01-012021-06-300000049071hum:RetailSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:SpecialtyMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:SpecialtyMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:SpecialtyMember2021-01-012021-06-300000049071hum:SpecialtyMember2021-01-012021-06-300000049071hum:MedicaidAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:MedicaidAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:MedicaidAndOtherMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:MedicaidAndOtherMember2021-01-012021-06-300000049071hum:MedicaidAndOtherMember2021-01-012021-06-300000049071hum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMember2021-01-012021-06-300000049071hum:HomeSolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HomeSolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:HomeSolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HomeSolutionsMemberhum:CorporateAndEliminationsMember2021-01-012021-06-300000049071hum:HomeSolutionsMember2021-01-012021-06-300000049071hum:ProviderServicesMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:ProviderServicesMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:ProviderServicesMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:ProviderServicesMember2021-01-012021-06-300000049071hum:ProviderServicesMember2021-01-012021-06-300000049071hum:ASOAndOtherMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:ASOAndOtherMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:ASOAndOtherMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:ASOAndOtherMember2021-01-012021-06-300000049071hum:ASOAndOtherMember2021-01-012021-06-300000049071hum:PharmacySolutionsMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:PharmacySolutionsMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberhum:PharmacySolutionsMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberhum:PharmacySolutionsMember2021-01-012021-06-300000049071hum:PharmacySolutionsMember2021-01-012021-06-300000049071us-gaap:ServiceMemberhum:RetailSegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071us-gaap:ServiceMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ServiceMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ServiceMember2021-01-012021-06-300000049071us-gaap:ServiceMember2021-01-012021-06-300000049071hum:RetailSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071us-gaap:ProductMemberhum:GroupAndSpecialtySegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:HealthcareServicesSegmentMemberus-gaap:ProductMemberus-gaap:OperatingSegmentsMember2021-01-012021-06-300000049071hum:CorporateAndEliminationsMemberus-gaap:ProductMember2021-01-012021-06-300000049071us-gaap:ProductMember2021-01-012021-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| | | | | |
☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2022
OR
| | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 1-5975
HUMANA INC.
| | |
(Exact name of registrant as specified in its charter) |
|
| | | | | | | | |
Delaware | | 61-0647538 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
500 West Main Street
Louisville, Kentucky 40202
(Address of principal executive offices, including zip code)
(502) 580-1000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
Title of each class | Trading Symbol | Name of each exchange on which registered |
Common stock, $0.16 2/3 par value | HUM | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | |
Large accelerated filer | ☒ | | Accelerated filer | ☐ |
| | | | |
Non-accelerated filer | ☐ | | Smaller reporting company | ☐ |
| | | | |
Emerging growth company | ☐ | | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.
| | | | | |
Class of Common Stock | Outstanding at June 30, 2022 |
$0.16 2/3 par value | 126,553,698 shares |
Humana Inc.
FORM 10-Q
JUNE 30, 2022
INDEX
| | | | | | | | |
| | Page |
Part I: Financial Information | |
Item 1. | Financial Statements (Unaudited) | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
Item 2. | | |
| | |
Item 3. | | |
| | |
Item 4. | | |
| | |
| |
| | |
Item 1. | | |
| | |
Item 1A. | | |
| | |
Item 2. | | |
| | |
Item 3. | | |
| | |
Item 4. | | |
| | |
Item 5. | | |
| | |
Item 6. | | |
| | |
| | |
| | |
| Certifications | |
Humana Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited) | | | | | | | | | | | |
| June 30, 2022 | | December 31, 2021 |
| (in millions, except share amounts) |
ASSETS | | | |
Current assets: | | | |
Cash and cash equivalents | $ | 5,153 | | | $ | 3,394 | |
Investment securities | 13,037 | | | 13,192 | |
Receivables, net of allowances of $72 in 2022 and $83 in 2021 | 3,369 | | | 1,814 | |
Other current assets | 5,393 | | | 6,493 | |
Current assets held-for-sale | 265 | | | — | |
Total current assets | 27,217 | | | 24,893 | |
Property and equipment, net | 3,121 | | | 3,073 | |
Long-term investment securities | 380 | | | 780 | |
Equity method investments | 174 | | | 141 | |
Goodwill | 8,911 | | | 11,092 | |
Other long-term assets | 3,690 | | | 4,379 | |
Long-term assets held-for-sale | 3,327 | | | — | |
Total assets | $ | 46,820 | | | $ | 44,358 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | | | |
Current liabilities: | | | |
Benefits payable | $ | 9,650 | | | $ | 8,289 | |
Trade accounts payable and accrued expenses | 5,787 | | | 4,509 | |
Book overdraft | 391 | | | 326 | |
Unearned revenues | 264 | | | 254 | |
Short-term debt | 1,541 | | | 1,953 | |
Current liabilities held-for-sale | 206 | | | — | |
Total current liabilities | 17,839 | | | 15,331 | |
Long-term debt | 11,290 | | | 10,541 | |
Other long-term liabilities | 1,907 | | | 2,383 | |
Long-term liabilities held-for-sale | 274 | | | — | |
Total liabilities | 31,310 | | | 28,255 | |
| | | |
Stockholders’ equity: | | | |
Preferred stock, $1 par; 10,000,000 shares authorized; none issued | — | | | — | |
Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,666,598 shares issued at June 30, 2022 and 198,648,742 shares at December 31, 2021 | 33 | | | 33 | |
Capital in excess of par value | 3,153 | | | 3,082 | |
Retained earnings | 24,511 | | | 23,086 | |
Accumulated other comprehensive (loss) income | (1,051) | | | 42 | |
Treasury stock, at cost, 72,112,900 shares at June 30, 2022 and 69,846,758 shares at December 31, 2021 | (11,156) | | | (10,163) | |
Noncontrolling interests | 20 | | | 23 | |
Total stockholders’ equity | 15,510 | | | 16,103 | |
Total liabilities and stockholders’ equity | $ | 46,820 | | | $ | 44,358 | |
See accompanying notes to condensed consolidated financial statements.
Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | Six months ended June 30, |
| 2022 | | 2021 | | 2022 | | 2021 |
| (in millions, except per share results) |
Revenues: | | | | | | | |
Premiums | $ | 22,266 | | | $ | 19,978 | | | $ | 44,969 | | | $ | 40,102 | |
Services | 1,349 | | | 491 | | | 2,613 | | | 957 | |
Investment income | 47 | | | 176 | | | 50 | | | 254 | |
Total revenues | 23,662 | | | 20,645 | | | 47,632 | | | 41,313 | |
Operating expenses: | | | | | | | |
Benefits | 19,099 | | | 17,149 | | | 38,724 | | | 34,445 | |
Operating costs | 3,173 | | | 2,116 | | | 6,059 | | | 4,123 | |
Depreciation and amortization | 175 | | | 144 | | | 345 | | | 286 | |
Total operating expenses | 22,447 | | | 19,409 | | | 45,128 | | | 38,854 | |
Income from operations | 1,215 | | | 1,236 | | | 2,504 | | | 2,459 | |
| | | | | | | |
Interest expense | 101 | | | 79 | | | 191 | | | 147 | |
Other (income) expense, net | (8) | | | 419 | | | (29) | | | 534 | |
Income before income taxes and equity in net earnings | 1,122 | | | 738 | | | 2,342 | | | 1,778 | |
Provision for income taxes | 427 | | | 183 | | | 713 | | | 416 | |
Equity in net earnings (losses) | 2 | | | 33 | | | (2) | | | 54 | |
Net income | $ | 697 | | | $ | 588 | | | $ | 1,627 | | | $ | 1,416 | |
Less: Net income attributable to noncontrolling interests | (1) | | | — | | | (1) | | | — | |
Net income attributable to Humana | $ | 696 | | | $ | 588 | | | $ | 1,626 | | | $ | 1,416 | |
Basic earnings per common share | $ | 5.50 | | | $ | 4.57 | | | $ | 12.83 | | | $ | 11.00 | |
Diluted earnings per common share | $ | 5.48 | | | $ | 4.55 | | | $ | 12.77 | | | $ | 10.94 | |
See accompanying notes to condensed consolidated financial statements.
Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | |
| Three months ended June 30, | | Six months ended June 30, |
| 2022 | | 2021 | | 2022 | | 2021 |
| (in millions) |
Net income attributable to Humana | $ | 696 | | | $ | 588 | | | $ | 1,626 | | | $ | 1,416 | |
Other comprehensive income: | | | | | | | |
Change in gross unrealized investment (losses) gains | (623) | | | 136 | | | (1,392) | | | (184) | |
Effect of income taxes | 144 | | | (31) | | | 320 | | | 42 | |
Total change in unrealized investment (losses) gains, net of tax | (479) | | | 105 | | | (1,072) | | | (142) | |
Reclassification adjustment for net realized gains | — | | | (9) | | | (27) | | | (64) | |
Effect of income taxes | — | | | 2 | | | 6 | | | 15 | |
Total reclassification adjustment, net of tax | — | | | (7) | | | (21) | | | (49) | |
Other comprehensive (loss) income, net of tax | (479) | | | 98 | | | (1,093) | | | (191) | |
Comprehensive income attributable to equity method investments | — | | | 10 | | | — | | | 16 | |
| | | | | | | |
Comprehensive income attributable to Humana | $ | 217 | | | $ | 696 | | | $ | 533 | | | $ | 1,241 | |
See accompanying notes to condensed consolidated financial statements.
Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common Stock | | Capital In Excess of Par Value | | Retained Earnings | | Accumulated Other Comprehensive Income (loss) | | Treasury Stock | | Noncontrolling Interests | | Total Stockholders’ Equity |
| Issued Shares | | Amount | | | | | | |
| (dollars in millions, share amounts in thousands) |
Three months ended June 30, 2022 |
Balances, March 31, 2022 | 198,649 | | | $ | 33 | | | $ | 3,103 | | | $ | 23,915 | | | $ | (572) | | | $ | (11,160) | | | $ | 23 | | | $ | 15,342 | |
Net income | | | | | | | 696 | | | | | | | 1 | | | 697 | |
Distribution to noncontrolling interest holders | | | | | | | | | | | | | (4) | | | (4) | |
| | | | | | | | | | | | | | | |
Other comprehensive loss | | | | | | | | | (479) | | | | | | | (479) | |
Common stock repurchases | | | | | — | | | | | | | (4) | | | | | (4) | |
Dividends and dividend equivalents | | | | | — | | | (100) | | | | | | | | | (100) | |
Stock-based compensation | | | | | 50 | | | | | | | | | | | 50 | |
Restricted stock unit vesting | 18 | | | — | | | (4) | | | | | | | 4 | | | | | — | |
Stock option exercises | — | | | — | | | 4 | | | | | | | 4 | | | | | 8 | |
Balances, June 30, 2022 | 198,667 | | | $ | 33 | | | $ | 3,153 | | | $ | 24,511 | | | $ | (1,051) | | | $ | (11,156) | | | $ | 20 | | | $ | 15,510 | |
| | | | | | | | | | | | | | | |
Three months ended June 30, 2021 |
Balances, March 31, 2021 | 198,649 | | | $ | 33 | | | $ | 2,712 | | | $ | 21,252 | | | $ | 108 | | | $ | (9,915) | | | $ | — | | | $ | 14,190 | |
Net income | | | | | | | 588 | | | | | | | — | | | 588 | |
Distribution to noncontrolling interest holders | | | | | | | | | | | | | — | | | — | |
| | | | | | | | | | | | | | | |
Other comprehensive income | | | | | | | | | 108 | | | | | | | 108 | |
Common stock repurchases | | | | | 263 | | | | | | | (265) | | | | | (2) | |
Dividends and dividend equivalents | | | | | — | | | (89) | | | | | | | | | (89) | |
Stock-based compensation | | | | | 45 | | | | | | | | | | | 45 | |
Restricted stock unit vesting | — | | | — | | | (3) | | | | | | | 3 | | | | | — | |
Stock option exercises | — | | | — | | | 1 | | | | | | | 2 | | | | | 3 | |
Balances, June 30, 2021 | 198,649 | | | $ | 33 | | | $ | 3,018 | | | $ | 21,751 | | | $ | 216 | | | $ | (10,175) | | | $ | — | | | $ | 14,843 | |
See accompanying notes to condensed consolidated financial statements.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| Common Stock | | Capital In Excess of Par Value | | Retained Earnings | | Accumulated Other Comprehensive Income (loss) | | Treasury Stock | | Noncontrolling Interests | | Total Stockholders’ Equity |
| Issued Shares | | Amount | | | | | | |
| (dollars in millions, share amounts in thousands) |
Six months ended June 30, 2022 |
Balances, December 31, 2021 | 198,649 | | | $ | 33 | | | $ | 3,082 | | | $ | 23,086 | | | $ | 42 | | | $ | (10,163) | | | $ | 23 | | | $ | 16,103 | |
Net income | | | | | | | 1,626 | | | | | | | 1 | | | 1,627 | |
Distribution to noncontrolling interest holders | | | | | | | | | | | | | (4) | | | (4) | |
| | | | | | | | | | | | | | | |
Other comprehensive loss | | | | | | | | | (1,093) | | | | | | | (1,093) | |
Common stock repurchases | | | | | — | | | | | | | (1,028) | | | | | (1,028) | |
Dividends and dividend equivalents | | | | | — | | | (201) | | | | | | | | | (201) | |
Stock-based compensation | | | | | 93 | | | | | | | | | | | 93 | |
Restricted stock unit vesting | 18 | | | — | | | (28) | | | | | | | 28 | | | | | — | |
Stock option exercises | — | | | — | | | 6 | | | | | | | 7 | | | | | 13 | |
Balances, June 30, 2022 | 198,667 | | | $ | 33 | | | $ | 3,153 | | | $ | 24,511 | | | $ | (1,051) | | | $ | (11,156) | | | $ | 20 | | | $ | 15,510 | |
| | | | | | | | | | | | | | | |
Six months ended June 30, 2021 |
Balances, December 31, 2020 | 198,649 | | | $ | 33 | | | $ | 2,705 | | | $ | 20,517 | | | $ | 391 | | | $ | (9,918) | | | $ | — | | | $ | 13,728 | |
Net income | | | | | | | 1,416 | | | | | | | — | | | 1,416 | |
Distribution to noncontrolling interest holders | | | | | | | | | | | | | — | | | — | |
| | | | | | | | | | | | | | | |
Other comprehensive loss | | | | | | | | | (175) | | | | | | | (175) | |
Common stock repurchases | | | | | 263 | | | | | | | (296) | | | | | (33) | |
Dividends and dividend equivalents | | | | | — | | | (182) | | | | | | | | | (182) | |
Stock-based compensation | | | | | 84 | | | | | | | | | | | 84 | |
Restricted stock unit vesting | — | | | — | | | (36) | | | | | | | 36 | | | | | — | |
Stock option exercises | — | | | — | | | 2 | | | | | | | 3 | | | | | 5 | |
Balances, June 30, 2021 | 198,649 | | | $ | 33 | | | $ | 3,018 | | | $ | 21,751 | | | $ | 216 | | | $ | (10,175) | | | $ | — | | | $ | 14,843 | |
Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| | | | | | | | | | | |
| For the six months ended June 30, |
| 2022 | | 2021 |
| (in millions) |
Cash flows from operating activities | | | |
Net income | $ | 1,627 | | | $ | 1,416 | |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: | | | |
| | | |
Losses (gains) on investment securities, net | 137 | | | (86) | |
| | | |
Equity in net losses (earnings) | 2 | | | (54) | |
Stock-based compensation | 93 | | | 84 | |
Depreciation | 369 | | | 308 | |
Amortization | 45 | | | 30 | |
Impairment on property and equipment | 140 | | | — | |
Provision for deferred income taxes | 167 | | | — | |
Changes in operating assets and liabilities, net of effect of businesses acquired: | | | |
Receivables | (1,733) | | | (1,285) | |
Other assets | (655) | | | (879) | |
Benefits payable | 1,361 | | | 300 | |
Other liabilities | (333) | | | (301) | |
Unearned revenues | 10 | | | 5 | |
Other | 31 | | | (15) | |
Net cash provided by (used in) operating activities | 1,261 | | | (477) | |
Cash flows from investing activities | | | |
| | | |
Acquisitions, net of cash and cash equivalents acquired | (167) | | | (325) | |
Purchases of property and equipment, net | (574) | | | (619) | |
Purchases of investment securities | (3,239) | | | (5,307) | |
Proceeds from maturities of investment securities | 947 | | | 1,627 | |
Proceeds from sales of investment securities | 1,363 | | | 2,421 | |
Net cash used in investing activities | (1,670) | | | (2,203) | |
Cash flows from financing activities | | | |
Receipts from contract deposits, net | 3,076 | | | 1,183 | |
Proceeds from issuance of senior notes, net | 744 | | | — | |
(Repayments) proceeds from issuance of commercial paper, net | (418) | | | 508 | |
| | | |
| | | |
Debt issue costs | (2) | | | (21) | |
Change in book overdraft | 65 | | | (84) | |
Common stock repurchases | (1,028) | | | (33) | |
Dividends paid | (191) | | | (173) | |
Other | (11) | | | 5 | |
Net cash provided by financing activities | 2,235 | | | 1,385 | |
Increase (decrease) in cash and cash equivalents | 1,826 | | | (1,295) | |
Cash and cash equivalents at beginning of period | 3,394 | | | 4,673 | |
Cash and cash equivalents at end of period (1) | $ | 5,220 | | | $ | 3,378 | |
(1) Includes $67 million of cash and cash equivalents classified as held-for-sale at June 30, 2022.
Humana Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)
(Unaudited)
| | | | | | | | | | | |
| For the six months ended June 30, |
| 2022 | | 2021 |
| (in millions) |
Supplemental cash flow disclosures: | | | |
Interest payments | $ | 171 | | | $ | 132 | |
Income tax payments, net | $ | 373 | | | $ | 386 | |
Details of businesses acquired in purchase transactions: | | | |
Fair value of assets acquired, net of cash and cash equivalents acquired | $ | 190 | | | $ | 602 | |
Less: Fair value of liabilities assumed | (23) | | | (277) | |
| | | |
| | | |
Cash paid for acquired businesses, net of cash and cash equivalents acquired | $ | 167 | | | $ | 325 | |
See accompanying notes to condensed consolidated financial statements.
Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. BASIS OF PRESENTATION AND SIGNIFICANT EVENTS
The accompanying condensed consolidated financial statements are presented in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the disclosures normally required by accounting principles generally accepted in the United States of America, or GAAP, or those normally made in an Annual Report on Form 10-K. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. For further information, the reader of this Form 10-Q should refer to our Form 10-K for the year ended December 31, 2021, that was filed with the Securities and Exchange Commission, or the SEC, on February 17, 2022. We refer to the Form 10-K as the “2021 Form 10-K” in this document. References throughout this document to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries.
The preparation of our condensed consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The areas involving the most significant use of estimates are the estimation of benefits payable, the impact of risk adjustment provisions related to our Medicare contracts, the valuation and related impairment recognition of investment securities, and the valuation and related impairment recognition of long-lived assets, including goodwill and indefinite-lived intangible assets. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates. Refer to Note 2 to the consolidated financial statements included in our 2021 Form 10-K for information on accounting policies that we consider in preparing our consolidated financial statements.
The financial information has been prepared in accordance with our customary accounting practices and has not been audited. In our opinion, the information presented reflects all adjustments necessary for a fair statement of interim results. All such adjustments are of a normal and recurring nature.
Value Creation Initiatives
During 2022, in order to create capacity to fund growth and investment in our Medicare Advantage business and further expansion of our Healthcare Services capabilities in 2023, we committed to drive additional value for the enterprise through cost saving, productivity initiatives, and value acceleration from previous investments. As a result of these initiatives, during the second quarter of 2022, we recorded a charge of $203 million, primarily related to asset and software impairment and abandonment in the amount of $140 million. These charges are included within operating costs in the condensed consolidated statements of income for the three and six months ended June 30, 2022, and were recorded at the corporate level and not allocated to the segments. Included in this charge is $21 million in future severance payments in connection with the optimization of our workforce to increase speed, agility, and the pace at which Humana must work as a large, integrated healthcare organization. We expect this liability to be primarily paid within the next 12 months and classified it as a current liability, included in trade accounts payable and accrued expenses.
COVID-19
The emergence and spread of the novel coronavirus, or COVID-19, beginning in the first quarter of 2020 has impacted our business. During periods of increased incidences of COVID-19, a reduction in non-COVID-19 hospital admissions for non-emergent and elective medical care have resulted in lower overall healthcare system utilization. At the same time, COVID-19 treatment and testing costs increased utilization. During the first half of 2022, we experienced lower overall utilization of the healthcare system than anticipated, as the reduction in COVID-19 utilization following the increased incidence associated with the Omicron variant outpaced the increase in non-COVID-19 utilization. The significant disruption in utilization during 2020 also impacted our ability to implement clinical initiatives to manage health care costs and chronic conditions of our members, and appropriately document their risk profiles, and, as such, significantly affected our 2021 revenue under the risk adjustment payment model for Medicare Advantage plans. Finally, changes in utilization patterns and actions taken in 2021 as a result of the COVID-19 pandemic, including the suspension of certain financial recovery programs for a period of time and
Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
shifting the timing of claim payments and provider capitation surplus payments, impacted our claim reserve development and operating cash flows for 2021.
Revenue Recognition
Our revenues include premium and service revenues. Services revenues include administrative service fees that are recorded based upon established per member per month rates and the number of members for the month and are recognized as services are provided for the month. Additionally, service revenues include net patient service revenues that are recorded based upon established billing rates, less allowances for contractual adjustments, and are recognized as services are provided. For more information about our revenues, refer to Note 2 to the consolidated financial statements included in our 2021 Form 10-K for information on accounting policies that we consider in preparing our consolidated financial statements. See Note 14 for disaggregation of revenue by segment and type.
At June 30, 2022, accounts receivable related to services were $490 million, including $178 million classified as held-for-sale at June 30, 2022. For the three and six months ended June 30, 2022, we had no material bad-debt expense and there were no material contract assets, contract liabilities or deferred contract costs recorded on the condensed consolidated balance sheet at June 30, 2022.
For the three and six months ended June 30, 2022, services revenue recognized from performance obligations related to prior periods (for example, due to changes in transaction price), was not material. Further, services revenue expected to be recognized in any future year related to remaining performance obligations was not material.
2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
In September 2018, the FASB issued new guidance related to accounting for long-duration contracts of insurers which revises key elements of the measurement models and disclosure requirements for long-duration contracts issued by insurers, including the amortization of deferred contract acquisition costs and the measurement of liabilities for future policy benefits using current, rather than locked-in, assumptions. The new guidance, limited to our Medicare supplement product which represent less than 1% of consolidated premiums and services revenues, is effective for us beginning with annual and interim periods in 2023 and, using a modified retrospective approach, is to be applied to contracts in force on the basis of their existing carrying value amounts at the beginning of the earliest period presented. We are currently evaluating the impact on our results of operations, financial position and cash flows.
There are no other recently issued accounting standards that apply to us or that are expected to have a material impact on our results of operations, financial condition, or cash flows.
Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
3. ACQUISITIONS AND DIVESTITURES
On April 21, 2022, we signed a definitive agreement with private investment firm Clayton, Dubilier & Rice, or CD&R, to divest a 60% interest in the Hospice and Personal Care divisions of Humana’s Kindred at Home subsidiary, or KAH Hospice, at an enterprise valuation of $3.4 billion. These divisions include patient-centered services for Hospice, Palliative, Community and Personal Care. Under the agreement, we will receive cash proceeds of approximately $2.8 billion, which includes a combination of debt repayments from KAH Hospice to Humana and equity proceeds from the 60% interest purchased by CD&R. The transaction is expected to close in the third quarter of 2022 and is subject to customary state and federal regulatory approvals.
As of June 30, 2022, we classified KAH Hospice as held-for-sale and aggregated KAH Hospice’s assets and liabilities separately on the balance sheet. With the fair value exceeding the carrying value of KAH Hospice’s net assets, the resulting gain will be recognized upon closing of the transaction. The ultimate gain to be recognized will reflect considerations for costs to sell, changes in the carrying value of net assets and the related tax effect. The carrying value of the assets and liabilities of KAH Hospice classified as held-for-sale approximates fair value. The amount of goodwill included in the carrying value is based on the relative fair value of the Home Solutions reporting unit included within the Healthcare Services segment.
During the three months ended June 30, 2022, Humana Inc., our parent company, recognized a deferred tax liability of approximately $167 million for the excess of the book basis over the tax basis of its KAH Hospice subsidiary because realization of the liability in the foreseeable future was apparent with the classification as held-for-sale at June 30, 2022. Upon closing of the transaction, the deferred tax liability will be adjusted to reflect any changes to the excess of the book basis over tax basis of the KAH Hospice subsidiary.
KAH Hospice revenues for the three and six months ended June 30, 2022 were $399 million and $781 million, respectively. KAH Hospice pretax earnings for the three and six months ended June 30, 2022 were $64 million and $126 million, respectively.
The assets and liabilities of KAH Hospice classified as held-for-sale are as follows:
| | | | | |
| June 30, 2022 |
| (in millions) |
Assets | |
Cash and cash equivalents | $ | 67 | |
Receivables, net of allowances | 178 | |
Other current assets | 20 | |
Current assets held-for-sale | 265 | |
Property and equipment, net | 41 | |
Goodwill | 2,331 | |
Other assets | 955 | |
Long-term assets held-for-sale | 3,327 | |
Total assets held-for-sale | $ | 3,592 | |
Liabilities | |
Trade accounts payable and accrued expenses | $ | 206 | |
Current liabilities held-for-sale | 206 | |
Other liabilities | 274 | |
Long-term liabilities held-for-sale | 274 | |
Total liabilities held-for-sale | $ | 480 | |
Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
On August 17, 2021, we acquired the remaining 60% interest in Kindred at Home, or KAH, the nation’s largest home health and hospice provider, from TPG Capital, or TPG, and Welsh, Carson, Anderson & Stowe, or WCAS, two private equity funds, or the Sponsors, for an enterprise value of $8.2 billion, which includes our equity value of $2.4 billion associated with our 40% minority ownership interest. We paid the approximate $5.8 billion transaction price (net of our existing equity stake) through a combination of debt financing, the assumption of existing KAH indebtedness and parent company cash.
During 2022 and 2021, we acquired various health and wellness related businesses which, individually or in the aggregate, have not had a material impact on our results of operations, financial condition, or cash flows. The results of operations and financial condition of these businesses acquired in 2022 and 2021 have been included in our condensed consolidated statements of income and condensed consolidated balance sheets from the respective acquisition dates. Acquisition-related costs recognized in 2022 and 2021 were not material to our results of operations. For asset acquisitions, the goodwill acquired is partially amortizable as deductible expenses for tax purposes. The pro forma financial information assuming the acquisitions had occurred as of the beginning of the calendar year prior to the year of acquisition, as well as the revenues and earnings generated during the year of acquisition, were not material for disclosure purposes.
Humana Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
(Unaudited)
4. INVESTMENT SECURITIES
Investment securities classified as current and long-term were as follows at June 30, 2022 and December 31, 2021, respectively:
| | | | | | | | | | | | | | | | | | | | | | | |
| Amortized Cost | | Gross Unrealized Gains | | Gross Unrealized Losses | | Fair Value |
| (in millions) |
June 30, 2022 | | | | | | | |
U.S. Treasury and other U.S. government corporations and agencies: | | | | | | | |
U.S. Treasury and agency obligations | $ | 568 | | | $ | — | | | $ | (43) | | | $ | 525 | |
Mortgage-backed securities | 3,332 | | | — | | | (392) | | | 2,940 | |
Tax-exempt municipal securities | 776 | | | 1 | | | (34) | | | 743 | |
Mortgage-backed securities: | | | | | | | |
Residential | 493 | | | — | | | (54) | | | 439 | |
Commercial | 1,582 | | | — | | | (109) | | | 1,473 | |
Asset-backed securities | 1,764 | | | — | | | (50) | | | 1,714 | |
Corporate debt securities | |